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Abstract
Introduction: The homeostasis of magnesium (Mg) is perturbed in chronic kidney disease. It has been supposed that plasma Mg 
has a principal role to regulate the secretion of parathyroid hormone (PTH). Plasma Mg is capable of modulating secretion of PTH. 
Recent investigations showed that low serum Mg levels in patients with kidney disease have been linked to increased mortality.
Objectives: The aim of this study was to determine the relationship between serum Mg and PTH levels in hemodialysis patients.
Patients and Methods: This cross-sectional study was conducted on 56 hemodialysis patients in hemodialysis center of Hajar hospital 
of Shahrekord in 2015. Regular hemodialysis patients who had at least three months history of dialysis were enrolled to the study. 
The serum levels of Mg, calcium, phosphorus, intact PTH (iPTH), alkaline phosphatase, albumin and bicarbonate were measured. 
Results: In this study, 61.5% of the 52 patients were male. Mean ± standard deviation (SD) of patients’ age was 60.5 ± 17.7 years 
with median of 63 years old. The average duration of dialysis was 44±39.5 months (median 36 months). Additionally the dialysis 
dose was 517 ± 479 weeks (median; 414 weeks). Mean ± SD of serum iPTH and Mg were 360.1 ± 238.2 pg/mL and 2.2 ± 0.2 mg/mL 
respectively. In this study we found a significantly positive correlation of iPTH with serum Mg levels (r = 0.28, P = 0.04).
Conclusion: This study shows impact of Mg on parathormone secretion. Our findings require further investigations with larger and 
multicentric studies. 
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Introduction
One of the most important disorders of chronic renal 
failure is chronic kidney disease–mineral bone disorder 
(1). Parathyroid hormone (PTH) is a principal parameter 
in the pathogenesis of bone disease in dialysis patients. 
The homeostasis of phosphorus, calcium, and magnesium 
(Mg) is distorted in chronic renal failure (2,3). Mg is 
largely excreted by kidney. The homeostasis of Mg is 
perturbed in chronic kidney disease. In fact, kidney has a 
fundamental role in the homeostasis Mg. The regulation 
of Mg metabolism is influenced by filtration and 
reabsorption (4). Hyperphosphatemia, hypermagnesemia 
and hypocalcemia are detectable in advanced chronic 
kidney disease. Disturbances in Mg metabolism in chronic 
renal failure may partly contribute to the development of 
chronic kidney disease–mineral bone disorder (5,6). It 
has been supposed that plasma Mg has a principal role 
to regulate the secretion of PTH. Plasma Mg is capable 
of modulating secretion of PTH. Recent investigations 
revealed low serum Mg levels in patients with kidney 
disease have been linked to increased mortality. It has 
been detected that that lower plasma Mg values are related 
to calcification of cardiac tissue and vessel walls which will 
increase mortality and morbidity in hemodialysis patients 
(5-9).
Objectives
The aim of this study was to assess the relationship of 
serum Mg with PTH in a group of hemodialysis patients.
Patients and Methods
Study population
The present cross-sectional study was conducted in the 
hemodialysis center of Hajar hospital of Shahrekord 
in 2015. Regular hemodialysis patients who had three 
months history of dialysis were included to the study. 
Exclusion criteria were any active or chronic infection and 
a history of malignancy. Around 52 eligible patients were 
included to the study.
 Blood samples were collected to assess levels of calcium, 
Mg, alkaline phosphatase, intact PTH, albumin, and 
vitamin D using special standard kits. Plasma HCO3 was 
assessed by arterial blood gas. The serum calcium levels 
of blood was corrected with regard to the albumin levels. 
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 Implication for health policy/practice/research/
medical education
In a study on 52 hemodialysis patients, we found a significantly 
positive correlation of iPTH with serum magnesium levels.
Duration of dialysis and dialysis doses (calculated by 
sessions of dialysis per week × duration of dialysis; dialysis 
doses) was assessed too.
The efficiency of hemodialysis was calculated by assessing 
the urea reduction rate (URR) (10).
Ethical issues 
The research followed the tenets of the Declaration of 
Helsinki. Written informed consent was obtained from all 
patients. This study was approved by Ethical Committee of 
Shahrekord University of Medical Sciences and extracted 
from M.D thesis.
Statistical analysis
For statistical analysis, descriptive data are expressed as 
mean ± SD. We applied Spearman’s correlation coefficient 
for correlations. All statistical analyses were performed 
using SPSS version 18 (SPSS Inc., Chicago, IL, USA). P 
values less than 0.05 were considered as significant level 
and the data were reported as mean ± SD.
Results
In this study, 61.5% of 52 patients were male. Mean ± SD 
of patients’ age was 60.5 ±17.7 years with median of 63 
years old (minimum age; 13 years old, maximum age; 52 
years old). The average duration of dialysis was 44 ± 39.5 
months (median 36 months). Additionally the dialysis 
dose was 517 ± 479 weeks (median; 414 weeks). URR was 
0.61 ± 0.16%. Mean±SD of serum iPTH and Mg were 
360.1 ± 238.2 pg/mL and 2.2 ± 0.2 mg/mL respectively. 
The result of laboratory assessments are shown in Table 1.
In this study we found a significantly positive correlation 
of iPTH with serum Mg levels (r = 0.28, P = 0.04, Figure 1).
Discussion
In this study we found a significant positive correlation 
of serum PTH with levels of plasma Mg. In a cross-
sectional study on 41 hemodialysis patients, Baradaran 
et al detected an inverse correlation, albeit insignificant, 
between serum Mg value and levels of iPTH (r = -0.30 
P = 0.079) (11). Likewise, in the study of Zeraati et al 
serum Mg levels was 1.00 + 0.14 mg/dL. They also found 
a weak and inverse relationship between Mg serum level 
and iPTH, which was not statistically significant. They 
observed an inverse significant correlation of Mg and 
PTH levels in patients with serum PTH of above 300 pg/
ml. However, in patients with serum PTH levels less than 
300 pg/mL, no correlation of serum Mg with PTH was 
detected (12). To find the association of serum Mg and 
intact parathormone levels in CKD patients just prior to 
beginning hemodialysis, Ohya et al conducted a study on 
1231 patients in nine Japanese centers who had started 
hemodialysis for end-stage renal disease. They found 
serum Mg levels were significantly elevated in patients 
with low iPTH (13). Consistent with above-mentioned 
studies, Navarro et al also detected an inverse correlation 
of serum Mg with PTH levels. The study conducted on 
110 hemodialysis individuals with mean age of 55 ± 14 
years and the duration of dialysis was 35 ± 28 months 
(14). To find association of serum PTH and Mg levels 
in continuous ambulatory peritoneal dialysis subjects 
using low-Mg peritoneal dialysate, Cho et al detected that 
parathormone level was not associated with serum Mg 
level. They found patients whose serum parathormone 
was less than 300 pg/mL, serum parathyroid levels were 
inversely associated with serum Mg level (15). 
Conclusion
To conclude, hypermagnesemia reduces PTH secretion, 
which is detected as a risk factor for calcification of 
vessel walls, hypertrophy of left ventricle and increasing 
mortality in hemodialysis. While numerous investigations 
have detected that patients with higher serum Mg tend to 
have lower PTH levels, some of these studies may have 
methodological limitations (16). 
Limitations of the study 
Proportion of hemodialysis patients is relatively small. We 
suggest larger multicentric investigations on this aspect of 
hemodialysis individuals.
Table 1. The result of laboratory assessments in patients undergoing 
hemodialysis
Variable Average ± SD
Calcium (mg/dL) 9.1 ± 0.53
Albumin (g/dL) 4.1 ± 0.36
Bicarbonate (mEq/L) 21.1 ± 2.8
ALP (IU/L) 266.2 ± 120.5
Phosphorus (mg/dL) 5.3 ± 1.1
Intact PTH (pg/mL) 360.1 ± 238.2
Mg (mg/dL) 2.2 ± 0.2
Vitamin D (ng/ml) 14.4 ± 5.5
Figure 1. Relationship of serum Mg with levels of parathormone.
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